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Objective To evaluate the impact of sodium benzoate and dextromethorphan treatment on patients with the
attenuated form of nonketotic hyperglycinemia.
Study design Families were recruited with 2 siblings both affected with attenuated nonketotic hyperglycinemia.
Genetic mutations were expressed to identify residual activity. The outcome on developmental progress and sei-
zures was compared between the first child diagnosed and treated late with the second child diagnosed at birth
and treated aggressively from the newborn period using dextromethorphan and benzoate at dosing sufficient to
normalize plasma glycine levels. Both siblings were evaluated with similar standardized neurodevelopmental mea-
sures.
Results In each sibling set, the second sibling treated from the neonatal period achieved earlier and more devel-
opmental milestones, and had a higher developmental quotient. In 3 of the 4 sibling pairs, the younger sibling had no
seizures whereas the first child had a seizure disorder. The adaptive behavior subdomains of socialization and daily
living skills improved more than motor skills and communication.
Conclusions Early treatment with dextromethorphan and sodiumbenzoate sufficient to normalize plasma glycine
levels is effective at improving outcome if used in childrenwith attenuated disease withmutations providing residual
activity and when started from the neonatal period. (J Pediatr 2016;170:234-9).
N
onketotic hyperglycinemia (NKH) is a neurometabolic disorder caused by deficient activity of the glycine cleavage
enzyme system. Classic NKH is caused by mutations in either the GLDC gene, encoding for the P-protein, or the
AMT gene, encoding for the T-protein.1,2 Patients with severe NKH present neonatally or in early infancy with lethargy
progressing to coma, transient apnea, and myoclonic movements. Patients develop intractable seizures, axial hypotonia, and
limb spasticity, and make no developmental progress.3 In contrast, patients with attenuated NKHmake variable developmental
progress resulting in mild to severe intellectual disability, no or treatable epilepsy, and mild to no spasticity.3,4 They often haveFrom the 1Department of Pediatrics, University of
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Current treatment consists of reducing the glycine levels with benzoate and
blocking the effect of excess glycine on the N-methyl-D-aspartate (NMDA)
receptors with dextromethorphan. Benzoic acid is activated to benzoyl-CoA,
then is conjugated with glycine to form hippurate, which is excreted in the urine,
thus, eliminating glycine and reducing glycine levels.7 The benzoate dose is
individually tailored with the aim of plasma glycine levels between 120 and
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AE Age equivalent
BASC Behavior Assessment System for Children
DQ Developmental quotient
Mullen scales Mullen Scales of Early Learning
NKH Nonketotic hyperglycinemia
NMDA N-methyl-D-aspartate
WPPSI Wechsler Preschool and Primary Scale of Intelligence
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Volume 170  March 2016glutamate receptor, whose overstimulation has been posed as
a component of the pathogenesis of NKH.9,10 Dextromethor-
phan is a weak inhibitor of this receptor, and its use can
decrease seizures in NKH.10-12
Treatment with sodium benzoate has been shown to
improve alertness allowing for more learning opportunities,
and to decrease the propensity for seizures.3,7,8,13,14 Treat-
ment with dextromethorphan improved seizures, and in
some patients appeared to improve alertness and
outcome.10,11,15,16 Yet, for many patients, combined
treatment with both benzoate and dextromethorphan failed
to improve outcome.15,17-19 In patients with severe NKH,
even when started in the early neonatal period, treatment
does not improve developmental outcome, which remains
severely impaired, and does not prevent the development
of severe therapy-resistant epilepsy, although treatment
may improve overall seizure control.17,18 These results have
resulted in justifiable skepticism about the benefits of this
treatment. However, previous studies have failed to take
into account the substantial genetic heterogeneity of NKH.
Genetic mutations have a strong impact on outcome
in NKH,5 and large intragenic genetic heterogeneity
complicates evaluating the impact of a treatment interven-
tion in NKH. Patients with 2 mutations without any residual
activity always have severe NKH, make no developmental
progress, and have a severe seizure disorder, regardless of
treatment even when initiated from birth.17 However,
patients with at least 1 missense mutation have variable
degrees of developmental progress. However, in attenuated
NKH, case reports have suggested that treatment may be
beneficial, but the response may be modified by the genetic
mutation and by the timing of initiation of therapy with
treatment in the first 2 years of life being critical.4,6,19,20
Patients with mild mutations such as p.Ala802Val made
variable to excellent neurodevelopmental progress with
treatment but not when untreated.6
The large genetic heterogeneity makes controlled studies of
outcome difficult. To control for genetic heterogeneity, we
studied 4 sibling pairs with attenuated NKH and with
mutations that confer residual activity. In these 4 sibling
pairs, we compared the effect on neurodevelopmental
outcome of early vs delayed treatment.Methods
The study was approved by the Colorado Multiple
Institutional Review Board (COMIRB 05-0790), and written
informed consent was obtained from subjects’ parents.
Families were identified where there were 2 siblings both
affected with attenuated NKH, and where the first sibling
was treated late and the subsequent sibling was treated early.
Data on clinical history, treatment history, and brain
magnetic resonance imaging were reviewed. Specific
attention was paid to the timing and effectiveness of treat-
ment, and presence of seizures and antiepileptic medications
used. Benzoate treatment was considered effective whenblood glycine levels were controlled in the normal range,8
and dextromethorphan was used at a dose of 3-12 mg/kg/d.
All patients were examined by a metabolic physician (J.H.
or J.C.) and by a pediatric neuropsychologist (K.B. or
A.H.). The genetic mutations were identified in each sibling
pair by sequencing of the GLDC gene.5 The residual activity
of the mutation was determined by expression of the
mutation in COS cells and measurement of the activity using
the glycine exchange reaction in the presence of recombinant
lipoylated human H-protein, and reported as percentage of
the wild type P-protein expressed in the same experiment
as previously described.5 The glycine index was calculated
by subtracting the molar glycine intake in food from a dietary
recall from the molar dose of sodium benzoate needed
to normalize plasma glycine levels divided by body
weight, which reflects a whole body balance of glycine
metabolism.8
Three sets of siblings were evaluated at Children’s
Hospital Colorado and University of Colorado including
age-appropriate neuropsychological evaluations; the fourth
family was evaluated in Sydney, Australia. The primary
outcome was overall neurocognitive ability. Different scales
were used in each family because of different ages and
developmental levels. At the University of Colorado,
children under the age of 6 years were given the Mullen
Scales of Early Learning (Mullen scales).21 Children older
than 6 years of age were administered one of the Wechsler
tests (Wechsler Intelligence Scale for Children, Fourth
Edition22 or Wechsler Preschool and Primary Scale of
Intelligence [WPPSI]23). All measures indicated full-scale
IQ scores with a mean of 100 and a SD of 15 representing
the average range of functioning and scores more than 2
SDs below the mean (ie, <70) representing impairment.
Because of the extent of their impairments, the WPPSI,
Third Edition was used in families 1 and 3,23 and the Mullen
scales used in family 2.21 The Mullen scales can be adminis-
tered to infants and children up to 68 months of age as a
measure of development. An Early Learning Composite
score (full scale IQ), and age-equivalents can be computed
separately for the 5 scales: gross motor, visual reception,
fine motor, expressive language, and receptive language.16
The WPPSI, Third Edition is a measure of verbal and
nonverbal reasoning abilities for preschool children.23
Patient 3B also completed an educational evaluation, using
the Battelle Developmental Inventory, Second Edition,
which is a standardized battery that assesses children in 5
domains: motor, cognitive, personal-social, adaptive, and
communication.24 In Sydney, at the age of 4 years family 4
was administered the Differential Ability Scales, Second
Edition, which is a nationally normed, individually
administered battery of cognitive and achievement tests
for a range of developmental levels.25 At age 8 years
3 months, family 4 completed the Wechsler Intelligence
Scale for Children, Fourth Edition.17 For each child, a
General Developmental Quotient was calculated. The
developmental quotient (DQ) is a measure of the rate of
development. By using the mean or median age at which a235
THE JOURNAL OF PEDIATRICS  www.jpeds.com Volume 170milestone presents, a functional age equivalent (AE) for a
child’s development is given. DQ is the ratio of
developmental AE to chronological age.
As a second outcome measure, in some families additional
testing was done to evaluate adaptive behavior, and visuomo-
tor, language, and emotional and behavioral functioning.
The Vineland Adaptive Behavior Scales were used to measure
daily functioning.26 The Vineland Adaptive Behavior Scale is
a widely used norm-referenced parent report measure of
personal and social sufficiency in the areas of communica-
tion, daily living skills, socialization, and motor function.
These domain areas are combined to form an adaptive
behavior composite score. Similar to IQ scores, domain areas
and the composite score have a mean of 100 and a SD of 15
with 2 SDs below the mean representing clinical impairment.
Visuomotor function was assessed by the Beery-Buktenica
Test of Visual Motor Integration.27 Receptive and expressive
language was assessed by Peabody Picture Vocabulary Test,
Fourth Edition,28 or the Clinical Evaluation of Language
Fundamentals–Preschool, Second Edition.29
Emotional and behavioral components were evaluated
with the Behavior Assessment System for Children (BASC),
Second Edition. The BASC, Second Edition is a standardized
rating scale that compares the child’s emotional and
behavioral functioning to that of peers of the same age using
t scores with a mean of 50 and SD of 10.30
Results
In 4 families, the first child was diagnosed and treated after
2-6 months, whereas the second child was diagnosed
prenatally or neonatally and treated effectively from the first
week with benzoate and dextromethorphan. The diagnosis,
symptoms, and developmental milestones are listed in
Table I.
Families 1, 2, and 3 were compound heterozygous for a
mutation affecting a conserved splice site, and a
missense mutation (Table II). Expression of the
missense mutations showed residual activities of 18.2%,
25.8%, and 11.9% of wild type for p.Ala202Val,
p.Ala802Val, and p.Ala389Val respectively. Family 4 was
homozygous for a missense mutation resulting in
p.Cys291Tyr, which had 1.1% of wild type residual activity
(Table II). The results of neurodevelopmental evaluations
are listed in Table III.
Family 1
Patient 1A was tested at age 11 years, 2 months with a DQ 37
and an AE of 4 years, 1 month. Her receptive language was at
4 years, 8 months and expressive language at 5 years,
7 months level. Visual motor integration skills were less
developed at an AE score of 3 years, 5 months. For adaptive
behaviors, her overall composite score was in the moderately
impaired range with a personal strength in socialization and
significant impairment in motor skills. She was echolalic, and
very fidgety, with intermittent attention. She demonstrated
affection.236Patient 1B was evaluated at age of 9 years resulting in a DQ
of 51 with an AE of 4 years, 7 months. Receptive language was
at 6 years, 2 months and expressive language at 4 years,
7 months level. Visual motor integration skills were in the
moderately impaired range with an AE score of 4 years,
6 months. In terms of adaptive behaviors, his overall
composite score was in the borderline range with AE scores
between 7 years, 6 months for communication, daily living
skills, and socialization, and only 1 year, 4 months for gross
motor skills. In terms of behavior, he was attentive but
sometimes impulsive, requiring additional time for
processing instructions. He was interactive but echolalic.
Family 2
Patient 2A was evaluated at age 4 years, 9 months resulting in
a DQ <20 in the markedly impaired range with an AE of
9 months. On the BASC, Preschool Version, his parents rated
his overall behavior in themoderately impaired range. On the
Vineland Adaptive Behavior Scales, his overall composite
score indicated he was markedly impaired with AE scores
ranging from less than 1 month to 8 months.
Patient 2B was evaluated at age 2 years, 5 months with a DQ
of 48. AE scores were 14 months for gross motor skills,
15months for visual reception, 17months for finemotor skills,
11 months for receptive language, and 8 months for expressive
language. For adaptive behavior, his overall composite score
indicated mildly impaired adaptive functions with AE scores
ranging from 7 months to 1 year, 6 months.
Family 3
Patient 3A was evaluated at the age of 5 years resulting in
overall cognitive abilities in the moderately impaired range
with a full scale IQ of 44, with consistent verbal and perfor-
mance cognitive abilities. Overall language abilities were in
the moderately impaired range with a standard score of 45.
In terms of adaptive behaviors, her overall composite score
was less developed and in the markedly impaired range
(standard score of 35), with AE scores ranging from less
than 1 month (communication) to 8 months (daily living
skills and motor skills).
Patient 3B was evaluated at the age of 14 months with an
overall DQ of 30. Adaptive behaviors were in the moderately
impaired range with an overall standard score of 51. At the
age of 2 years, 11 months, she completed an educational eval-
uation receiving an overall standard score of 55 in cognitive
abilities, with comparative adaptive development (standard
score of 55) with AEs ranging from 6 months to <24 months.
Family 4
Patient 4A appeared normal until he developed a rapidly
worsening epileptic encephalopathy at age 6 months. His sei-
zures became intractable; he lost all developmental skills, and
died at age 13 months. His developmental status was never
formally tested. Patient 4B had a cognitive assessment at
age 4 years, 4 months with an overall IQ of 78. He had
mild to moderate receptive language and severe expressive
language deficit. At age 6 years, on the Clinical EvaluationBjoraker et al
Table I. Clinical findings in 4 siblings pairs with attenuated NKH
Case 1A Case 1B Case 2A Case 2B Case 3A Case 3B Case 4A Case 4B
Clinical presentation and
diagnosis
Presentation 1 d 1 d 1 d 5 d 3 mo 6 mo
Diagnosis 2 mo Prenatal 6 mo Prenatal 1 mo Prenatal 6 mo Neonatal
Symptoms Hypotonia,
lethargic,
myoclonic
jerks
Hypotonia Seizures Delayed
development
Lethargy,
seizures
Seizures,
regression
Delayed
development
Biochemical findings at
diagnosis and treatment
Glycine, plasma (mM)* 578 (<436) 294 (<540) 552 (<436) 693 (<540) 637 (<436) 536 (<540) 961 (<436) 713 (<540)
Glycine, CSF (mM)* 89 (<20) NA 103 (<12) 85 (<20) 136 (<20) NA 52 (<12) 47 (<20)
CSF:Plasma glycine* 0.15 (<0.02) NA 0.17 (<0.02) 0.12 (<0.02) NA NA 0.05 (<0.02) 0.07 (<0.02)
Treatment achieved 6 mo First wk 7 mo First wk 6-8 wk First wk 6 mo First wk
Glycine index (mmol/kg/d) 2.77 2.65 2.30 1.84 2.52 0.68 NA NA
Developmental milestones
Reaching/grasping 9 mo 6 mo 2-3 y 9 mo 6 y 1 y 5 mo 3 mo
Independent sit 1 y 8 mo 7 mo 3 y 1 y 5 mo 2.5 y 1 y 3 mo No 10 mo
Independent walk 5 y 2 y 6 mo Stand only
(4 y)
1 y 10 mo With walker
only
With walker
only
14 mo
First words 1 y 11 mo 1 y 4 mo 6 y (1 word) 3 y 6 mo No words 14 mo (few) 16 mo
Clinical evaluation
Age at evaluation 11 y 2 mo 9 y 4 y 10 mo 2 y 5 mo 6 y 6 mo
(deceased,
7 y)
14 mo NA (deceased,
13 mo)
5 y 7 mo
ADHD Yes Yes No No No No Yes
Chorea Yes (mild) Yes (mild) Yes Yes Yes No No
Dysmetria Yes (mild) Yes (mild) No No No No No
Hyperreflexia Yes Yes Yes No Yes No No
Temper tantrums Yes No No Yes No No No
NA, not available; CSF, cerebrospinal fluid; ADHD, attention deficit hyperactivity disorder.
The biochemical diagnostic findings, symptoms, and developmental milestones are provided.
*Normal values are in parenthesis.
March 2016 ORIGINAL ARTICLESof Language Fundamentals Fourth Edition, he had a core lan-
guage index standard score of 63 with only word structure at
the lowest end of the normal range, and great difficulties with
concepts and following directions, recalling sentences, and
formulating sentences. A repeat cognitive assessment at age
8 years, 3 months was consistent with his earlier assessment.
Overall, he functioned in the borderline range of intellectual
ability (IQ of 75). He had difficulty with all aspects of
attention and was easily distracted. Areas of personal strength
were in motor speed, word reading, and spelling, which were
average.Discussion
The overall goal of neurodevelopmental evaluations is
to identify brain and behavior abnormalities that can beTable II. Mutations and residual enzyme activities
Family Family 1
Paternal mutation c. 2665+1G>C c.2665+
Effect p.IVS22+1G>C, missplicing p.IVS22
Maternal mutation c. 605C>T c.2405C
Effect p.Ala202Val, missense p.Ala802
Residual activity of missense mutation* 18.2%  3.43% 25.8% 
The mutations present in each family and the residual activity of the expressed missense mutation
*Residual activity values are expressed relative to the mean of normal in assay control and SD of r
Neurodevelopmental Outcome and Treatment Efficacy of Benzo
with Attenuated Nonketotic Hyperglycinemiasensitive to changes resulting from treatment. Neurodevelop-
mental testing serves as a sensitive measure of disease severity
and can be used to measure disease progression and
treatment outcome. Quantified comparisons with age mates
allows for measurement of the severity of deficits. Here we
report detailed neurodevelopmental testing in siblings with
attenuated NKH and use this measure to indicate the impact
of treatment. Because of a wide range of developmental levels,
different instruments were used; however, within the same
family similar rating instruments were used for both siblings
thus allowing a direct comparison between them.
In this study, we aimed to evaluate whether current
treatment with sodium benzoate and dextromethorphan
influenced neurocognitive outcome specifically in those
patients with attenuated NKH. To control for genetic
heterogeneity, we comparatively studied pairs of patients
with similar mutations such as siblings, similar to whatFamily 2 Family 3 Family 4
1G>A c.1166C>T c.872G>A
+1G>A, missplicing p.Ala389Val, missense p.Cys291Tyr, missense
>T c.1580+2T>G c.872G>A
Val, missense p.IVS12+2T>G, missplicing p.Cys291Tyr, missense
4.4% 11.9%  2.53% 1.1%  0.33%
are provided.
eplicate assays.
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Table III. Comparison of sibling pairs on developmental outcome
1A 1B 2A 2B 3A 3B 4A 4B
Sex Female Male Male Male Female Female Male Male
Age at evaluation 11 y 2 m 9 y 4 y 9 m 2y 5 m 5 y 1 y 2 m Deceased 8 y 3 m
Seizures 6 w to 4 y Never 6 w to 6 y Never From 4 d From 3 m From 6 m Never
IQ or GDQ DQ 37 DQ 51 DQ <20 DQ 48 IQ 44 IQ 55 - IQ 75
Adaptive functions
Communication 54 77 42 69 40 52 - Not given
Daily living 59 71 40 67 38 21
Socialization 66 73 46 74 48 82
Motor skills * * 37 72 28 57
Composite 59 72 40 67 35 51
BASC BSI t score 63 62 54 53
BSI, Behavioral Symptoms Index; GDQ, General Developmental Quotient.
The results of cognitive testing, using testing as outlined in the text for each family, are provided as either an IQ or as a GDQ. The standard scores on the Vineland Adaptive Behavior Scales with
subdomain scores. The BASC, Second Edition BSI t scores are reported with average range of 40-60.
*Not able to evaluate based on performance of the national standardization sample of the items of the motor skills domain, which are appropriate for individuals through ages <6 y.
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vention in an equally genetically heterogeneous condition
such as pyruvate dehydrogenase deficiency.31 Each family
had 1 allele carrying a mutation that resulted in residual
activity, thus, allowing at least the potential for develop-
mental progress. In families 1-3, the second allele was a
consensus splice site mutation with likely no effective pro-
tein made, and the potential confounding effect of a domi-
nant negative missense mutation was avoided. We showed
in these 4 kindreds that the child who was treated from
birth with a combination of benzoate sufficient to control
glycine levels (<400 mM) and with dextromethorphan
($3 mg/kg/d for at least the first 2 years) progressed sub-
stantially better than their siblings who had been late
treated. This was evident on cognitive abilities, communi-
cation skills, and adaptive skills, but not on the emotional
and behavioral scale, either through standardized testing
or during clinical interviewing. Almost all patients had
chorea and hyperactivity regardless of treatment. In each
family, the second sibling, who had been treated since
the neonatal period, achieved milestones earlier and
acquired more skills than the first sibling. Seizures were
less frequent and less severe in the second sibling in 3 of
4 families. Similar to what was noted previously, there
did not appear to be a relation between the amount of
residual activity in the expression results and outcome.5
Patient 4B with the best outcome had the lowest residual
activity, but was the only patient with 2 alleles with
residual activity.
Thus, some residual activity is required for developmental
progress to be possible. In this setting, early treatment in the
first weeks to months of life is important to obtain optimal
results of current therapeutic intervention. Hypotheses for
this critical time vulnerability include the ontogeny of neuro-
transmitter receptors such as the NMDA receptor6,12,32 or the
prevention of irreversible early brain damage.20 Regardless of
the underlying mechanism, these data indicate that for
patients with attenuated NKH, when the patient carries at
least 1 mutation that confers residual activity, it is important
for optimal outcome to initiate therapy promptly and to
maintain this throughout the early years. This study does238not make it possible to distinguish whether 1 component
of this therapy was more important than the other, or for
how long therapy should be continued. In the study by
Korman et al,6 therapy was discontinued without adverse
effect in one patient after 2 years, but other patients have
experienced adverse effects upon discontinuation of treat-
ment.14 Both dextromethorphan and ketamine have been
used as a partial NMDA receptor antagonist in NKH, and
which treatment or any other NMDA receptor antagonist is
more effective remains to be evaluated.6,12,20,33
We conclude that in attenuated NKH, treatment with
sodium benzoate and dextromethorphan improves neuro-
cognitive outcome when instituted early. This is in contrast
to the lack of efficacy in those patients with severe NKH.
For patients in whom mutations conferring residual activity
are identified, therapy should be pursued early and strictly to
allow optimal outcome. Treatment may be a modifying
factor of the genotype-phenotype relation in patients with
attenuated NKH. n
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